New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:19 EDTGSK, PTXClosing of Pernix transaction to acquire Treximet tablets from GSK delayed
Pernix Therapeutics Holdings (PTX) announced that the closing of its transaction to acquire the U.S. rights to Treximet for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The company is working with GlaxoSmithKline (GSK) to ensure sufficient supply to meet anticipated demand. The company and its lenders are also performing additional due diligence related to this supply issue. Doug Drysdale, Chairman, President and CEO of Pernix said, “We are working with our lenders to complete our review and remain optimistic about our ability to close the acquisition of Treximet. We hope to complete our due diligence and the financing necessary in the near future.”
News For PTX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information
December 5, 2014
06:04 EDTGSKGSK won't pursue divestment of certain brands in established products portfolio
As announced at the company’s Q2 results in July, GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio.The company has evaluated all bids received and has concluded, consistent with its key criteria of maximizing shareholder value, not to pursue divestment of these products.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use